Medacta Q2 Results Beat Expectations, Maintains 2026 Guidance

LootboxPhobia · 2026-03-13T13:07:55+00:00

Swiss medical device manufacturer Medacta reported better-than-expected adjusted EBIT for the second half of the year, with EBITDA reaching €92 million and sales growth of 17% at constant exchange rates. The company projects revenue growth of 10-14% for 2026, which is consistent with analyst expectations, while also providing higher revenue growth guidance for 2024-27.

LootboxPhobia

2026-03-13 13:07:55

Abstract generation in progress

Investing.com – Swiss medical device manufacturer Medacta Group SA (SIX:MOVE) announced on Friday that its adjusted EBIT for the second half of the year exceeded market expectations by 1%, and its 2026 guidance at the median level is in line with analyst forecasts.

The company’s adjusted EBITDA for the second half was €92 million, 3% above market expectations, thanks to better operating expense management, although gross margin appears to be below analyst model predictions.

Adjusted EBIT was €52 million, slightly higher than market expectations. Previously disclosed group sales increased by 17% in the second half at constant exchange rates.

UBS noted that free cash flow from equity during this period was negative €3 million, an improvement from negative €8 million in 2024.

For 2026, Medacta’s management expects revenue growth of 10-14% at constant exchange rates, with EBITDA margin expanding by 50 basis points.

UBS believes that after considering foreign exchange headwinds, this guidance at the median level is in line with market expectations.

The company also provided the latest mid-term guidance for 2024-27, with revenue growth of 12-15% at constant exchange rates, higher than the previous guidance of 10-14%.

Management stated that profit margins at constant exchange rates will gradually improve, whereas the previous guidance was approximately 28% before considering foreign exchange headwinds.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.